Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients | Zendy

George A. Kaysen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients

Author(s) -

George A. Kaysen

Publication year - 2017

Publication title -

blood purification

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.686

H-Index - 57

eISSN - 1421-9735

pISSN - 0253-5068

DOI - 10.1159/000452727

Subject(s) - medicine , fenofibrate , dialysis , renal replacement therapy , kidney disease , renal function , wasting , disease , diabetes mellitus , risk factor , cause of death , endocrinology

Chronic kidney disease is associated with a 15-fold increase in the risk of death and a 30-fold increase in the risk of cardiovascular events even prior to dialysis initiation, and this situation remains unchanged following the initiation of the dialysis procedure. Lipoprotein structure and function, especially the anti-oxidative properties of high-density lipoprotein, are altered. In this study, the effectiveness of lipid-lowering therapy on mortality and cardiovascular outcomes is explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research